What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Molecular Basis of Cancer: From Oncogenes to Tumor Suppressors

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to the Molecular Basis of Cancer

What is Cancer?

Cancer is a collection of diseases characterized by uncontrolled cell division, resistance to normal cell death signals, and the capacity to invade surrounding tissues and spread to distant sites. At its core, cancer is a disorder of the genome—a disease driven by alterations in the DNA sequence and epigenetic state of somatic cells. These alterations accumulate over time, progressively transforming a normal cell into a malignant one through a process called clonal evolution.

Clonal evolution describes the stepwise acquisition of mutations within a single cell lineage. Each mutation that confers a growth advantage—allowing the cell to divide faster, resist apoptosis, or evade immune detection—results in the expansion of that cell's progeny. Over years or decades, successive rounds of mutation and selection produce a tumor composed of genetically heterogeneous cells, all descended from a common ancestral cell but differing in their mutational profiles. This heterogeneity is a major reason why cancers can be difficult to treat: different subclones within the same tumor may respond differently to therapy, and pre-existing resistant subclones can expand under selective pressure.

Cancer as a Genetic Disease

The genetic basis of cancer was firmly established through decades of research combining cytogenetics, molecular cloning, and, more recently, high-throughput DNA sequencing. Three classes of genes are central to cancer pathogenesis: proto-oncogenes, tumor suppressor genes, and DNA repair genes. Proto-oncogenes promote cell growth and division; when mutated into oncogenes, they become hyperactive or constitutively active. Tumor suppressor genes restrain cell growth; when inactivated, their braking function is lost. DNA repair genes maintain genomic integrity; when defective, they allow mutations to accumulate at an accelerated rate.

The distinction between these classes is fundamental. Oncogenes act dominantly: a single mutant allele is sufficient to drive aberrant signaling. Tumor suppressor genes act recessively at the cellular level: both alleles typically must be inactivated for loss of function. DNA repair genes behave like tumor suppressors in this regard, but their inactivation produces a mutator phenotype that indirectly promotes cancer by increasing the mutation rate across the entire genome. This framework, first articulated by Alfred Knudson and later refined by many others, remains the organizing principle of cancer molecular biology. For a broader overview of how these genetic changes translate into cellular behavior, see the Molecular Mechanism of Cancer.

Oncogenes and Tumor Suppressor Genes

Proto-oncogenes and Oncogenes

Proto-oncogenes are normal cellular genes that encode proteins involved in growth factor signaling, signal transduction, transcription regulation, and cell cycle control. They are tightly regulated in normal cells, active only when the cell receives appropriate extracellular signals. When mutated or overexpressed, they become oncogenes—genes that drive cell proliferation in an unregulated manner.

The conversion of a proto-oncogene to an oncogene can occur through several mechanisms:

Point mutation that produces a constitutively active protein. The classic example is the RAS family of genes (HRAS, KRAS, NRAS). RAS proteins are small GTPases that cycle between an active GTP-bound state and an inactive GDP-bound state. Mutations at codons 12, 13, or 61 abolish GTPase activity, locking RAS in the active conformation. This results in continuous activation of downstream pathways, including the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade and the PI3K-AKT pathway. Approximately 20–30% of all human tumors harbor activating RAS mutations, with KRAS being the most frequently mutated family member.

Gene amplification that increases the copy number of a proto-oncogene, leading to protein overexpression. ERBB2 (also known as HER2), a receptor tyrosine kinase, is amplified in approximately 20% of breast cancers. Amplification can involve hundreds of copies of the gene, resulting in massively increased receptor density on the cell surface and ligand-independent dimerization and signaling.

Chromosomal translocation that places a proto-oncogene under the control of a highly active promoter or creates a fusion gene encoding a chimeric protein with aberrant activity. The Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), creates the BCR-ABL1 fusion gene. The resulting BCR-ABL1 protein is a constitutively active tyrosine kinase that drives chronic myeloid leukemia. This translocation is the molecular target of imatinib, a small-molecule kinase inhibitor that has transformed the treatment of this disease.

Retroviral insertion or enhancer hijacking, in which a viral genome or regulatory element integrates near a proto-oncogene and drives its overexpression. This mechanism is more relevant in animal models and certain virally induced human cancers, such as hepatitis B virus integration near TERT in hepatocellular carcinoma.

Oncogenes are classified by the functional category of their protein products: growth factors (e.g., PDGFB), growth factor receptors (e.g., EGFR, ERBB2), signal transducers (e.g., RAS, BRAF), transcription factors (e.g., MYC, MYB), and cell cycle regulators (e.g., CCND1 encoding cyclin D1). The unifying theme is that oncogene activation provides a cell-autonomous proliferative signal that does not require external growth stimuli.

Tumor Suppressor Genes

Tumor suppressor genes encode proteins that inhibit cell proliferation, promote apoptosis, or maintain genomic stability. Their inactivation removes critical brakes on cell growth. Unlike oncogenes, which act dominantly, tumor suppressor genes are typically recessive at the cellular level: both alleles must be inactivated for the phenotype to manifest.

The best-characterized tumor suppressor is TP53, which encodes the p53 protein. p53 is a transcription factor that responds to cellular stress—DNA damage, oncogene activation, hypoxia, and nucleotide depletion—by inducing cell cycle arrest, senescence, or apoptosis. It is mutated in approximately 50% of all human cancers, making it the most frequently mutated gene in cancer. Most TP53 mutations are missense mutations in the DNA-binding domain, which produce a full-length protein that cannot bind DNA or activate target genes. Some mutant p53 proteins also acquire dominant-negative activity, forming inactive oligomers with wild-type p53, or gain novel oncogenic functions.

Other important tumor suppressors include:

RB1, encoding the retinoblastoma protein, which regulates the G1/S cell cycle checkpoint by binding and inhibiting E2F transcription factors. Loss of RB1 function allows unscheduled entry into S phase.
PTEN, a lipid phosphatase that opposes PI3K signaling by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Loss of PTEN results in hyperactivation of the AKT pathway.
APC, a component of the β-catenin destruction complex. Loss of APC leads to constitutive Wnt pathway activation and is the initiating event in most colorectal cancers.
CDKN2A, which encodes two proteins, p16^INK4a and p14^ARF, through alternative reading frames. p16 inhibits CDK4/6, while p14 stabilizes p53 by inhibiting MDM2.

Tumor suppressor genes can be inactivated by point mutations, deletions, promoter hypermethylation, or loss of heterozygosity (LOH). LOH refers to the loss of the remaining wild-type allele through chromosomal deletion, mitotic recombination, or gene conversion, leaving the cell with only the mutant allele.

Knudson's Two-Hit Hypothesis

In 1971, Alfred Knudson analyzed the age-specific incidence of retinoblastoma, a childhood eye tumor, and proposed that two mutational events ("hits") are required for tumor development. In hereditary retinoblastoma, the first hit is inherited in the germline, meaning every cell in the body already carries one mutant RB1 allele. A single somatic mutation in any retinal cell is then sufficient to inactivate the second allele, explaining the early onset and multifocal nature of hereditary retinoblastoma. In sporadic retinoblastoma, both hits must occur somatically in the same retinal cell, an event of low probability that explains the later onset and unifocal presentation.

The two-hit hypothesis has been validated for many tumor suppressor genes. However, it is important to recognize that some tumor suppressors exhibit haploinsufficiency, meaning that loss of a single allele contributes to tumorigenesis even before the second allele is lost. For example, heterozygous loss of PTEN in mice produces a cancer predisposition phenotype, and some mutant p53 proteins exert dominant-negative effects. The two-hit model is therefore a useful framework, but the reality is more nuanced. The Genetic Basis of Cancer article provides additional context on hereditary cancer syndromes and their underlying mutations.

DNA Repair Mechanisms and Genomic Instability

Types of DNA Repair

Cells have evolved multiple, partially overlapping DNA repair pathways to cope with different types of DNA damage. Defects in any of these pathways can lead to the accumulation of mutations and chromosomal aberrations—a state known as genomic instability. Genomic instability is a hallmark of cancer cells and is both a cause and a consequence of malignant transformation.

The major DNA repair pathways include:

Base Excision Repair (BER): Repairs small, non-helix-distorting base lesions, such as oxidized or alkylated bases. DNA glycosylases recognize and remove the damaged base, creating an abasic site that is processed by AP endonuclease, DNA polymerase β, and DNA ligase. Defects in BER are associated with hereditary colorectal cancer (biallelic MUTYH mutations).

Nucleotide Excision Repair (NER): Removes bulky, helix-distorting lesions, such as UV-induced pyrimidine dimers and chemical adducts. NER involves damage recognition, unwinding of the DNA duplex by TFIIH helicases (XPB and XPD), incision on both sides of the lesion by XPF-ERCC1 and XPG, excision of a 24–32 nucleotide single-stranded fragment, and gap-filling synthesis. Defects in NER cause xeroderma pigmentosum, a condition characterized by extreme UV sensitivity and a >1000-fold increased risk of skin cancer.

Mismatch Repair (MMR): Corrects base-base mismatches and small insertion/deletion loops that escape DNA polymerase proofreading during replication. The MutSα complex (MSH2-MSH6) recognizes base mismatches, while MutSβ (MSH2-MSH3) recognizes insertion/deletion loops. MutLα (MLH1-PMS2) then coordinates excision and resynthesis. Defects in MMR cause Lynch syndrome (hereditary non-polyposis colorectal cancer) and produce tumors with microsatellite instability—length alterations in repetitive DNA sequences.

Homologous Recombination (HR): Repairs DNA double-strand breaks (DSBs) using the sister chromatid as a template, providing error-free repair. Key proteins include MRE11-RAD50-NBS1 (MRN complex), BRCA1, BRCA2, and RAD51. BRCA1 and BRCA2 are essential for HR; their loss predisposes to breast, ovarian, prostate, and pancreatic cancers. HR-defective tumors are exquisitely sensitive to PARP inhibitors, which exploit the synthetic lethality between PARP inhibition and HR deficiency.

Non-Homologous End Joining (NHEJ): Repairs DSBs by directly ligating the broken ends without a template. NHEJ is error-prone and can introduce small insertions or deletions at the repair site. It is the dominant DSB repair pathway in G1 phase of the cell cycle. Ku70/Ku80 heterodimer binds the DNA ends, recruits DNA-PKcs, and the ligase complex (XRCC4-DNA ligase IV) seals the break.

Fanconi Anemia Pathway: Repairs DNA interstrand crosslinks, which block replication and transcription. This pathway involves at least 22 proteins (FANCA through FANCW) that coordinate nucleolytic incision, translesion synthesis, and HR. Biallelic mutations cause Fanconi anemia, characterized by bone marrow failure, developmental abnormalities, and cancer predisposition.

Hereditary Cancer Syndromes

Hereditary cancer syndromes result from germline mutations in DNA repair genes or tumor suppressors. These syndromes account for approximately 5–10% of all cancers and are characterized by early onset, multiple primary tumors, and a positive family history. Key examples are summarized in the table below.

Syndrome	Gene(s)	DNA Repair Pathway	Associated Cancers
Lynch syndrome	MLH1, MSH2, MSH6, PMS2	Mismatch repair	Colorectal, endometrial, ovarian, gastric
Hereditary breast and ovarian cancer	BRCA1, BRCA2	Homologous recombination	Breast, ovarian, prostate, pancreatic
Li-Fraumeni syndrome	TP53	Multiple pathways (p53-dependent responses)	Sarcomas, breast, brain, adrenal
Familial adenomatous polyposis	APC	Wnt signaling (not a repair gene)	Colorectal
Xeroderma pigmentosum	XPA–XPG, POLH	Nucleotide excision repair	Skin
Ataxia-telangiectasia	ATM	DSB signaling	Lymphoid, breast
Fanconi anemia	FANCA–FANCW	Interstrand crosslink repair	Leukemia, squamous cell carcinoma

The molecular basis of these syndromes illustrates a general principle: when a specific DNA repair pathway is defective, the types of mutations that accumulate reflect the lesions that pathway normally handles. MMR defects produce point mutations and microsatellite instability; NER defects produce UV-signature mutations (C→T transitions at dipyrimidine sites); HR defects produce large-scale chromosomal rearrangements and copy number alterations. This mutational signature analysis is now used diagnostically to identify the underlying repair defect in individual tumors.

Apoptosis and Cell Death Evasion

The Apoptotic Pathway

Apoptosis is a form of programmed cell death characterized by cell shrinkage, chromatin condensation, DNA fragmentation, and membrane blebbing, culminating in the formation of apoptotic bodies that are phagocytosed by neighboring cells. Apoptosis is executed by caspases, a family of cysteine-aspartic proteases that cleave hundreds of cellular substrates.

Two principal pathways activate caspases:

The intrinsic (mitochondrial) pathway: Triggered by intracellular stresses such as DNA damage, growth factor withdrawal, and oncogene activation. These signals converge on the Bcl-2 family of proteins, which regulate mitochondrial outer membrane permeabilization (MOMP). Pro-apoptotic BH3-only proteins (e.g., BIM, BID, PUMA, NOXA) antagonize anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1) and activate the effector proteins BAX and BAK. Activated BAX and BAK oligomerize in the outer mitochondrial membrane, forming pores that release cytochrome c. Cytochrome c, together with APAF-1 and dATP, assembles the apoptosome, which activates caspase-9. Caspase-9 then cleaves and activates executioner caspases-3 and -7.

The extrinsic (death receptor) pathway: Triggered by ligands such as Fas ligand (FasL) and tumor necrosis factor (TNF) binding to death receptors on the cell surface. Receptor trimerization recruits FADD and procaspase-8 to form the death-inducing signaling complex (DISC), leading to caspase-8 activation. Caspase-8 can directly activate caspase-3 or amplify the signal by cleaving BID to its truncated form (tBID), which engages the mitochondrial pathway.

p53 and Apoptosis

p53 sits at the nexus of the DNA damage response and apoptosis. In response to DNA damage, ATM and ATR kinases phosphorylate p53, stabilizing it by disrupting its interaction with MDM2, the E3 ubiquitin ligase that targets p53 for proteasomal degradation. Stabilized p53 accumulates in the nucleus and transcriptionally activates hundreds of target genes, including:

CDKN1A (encoding p21^Cip1), which causes G1 cell cycle arrest
BAX, PUMA (BBC3), and NOXA (PMAIP1), which promote apoptosis
MDM2, which creates a negative feedback loop
TIGAR, which modulates glycolysis and redox balance
SESN1 and SESN2, which activate AMPK and inhibit mTOR

The decision between cell cycle arrest and apoptosis depends on the cellular context, the intensity of the damage signal, and the expression of pro- versus anti-apoptotic Bcl-2 family members. In cells with high levels of survival signals (e.g., activated AKT), p53 may induce arrest and repair; in cells with sustained damage or oncogenic stress, p53 commits the cell to apoptosis.

Cancer cells evade apoptosis through multiple mechanisms:

Loss of p53 function (mutation or deletion of TP53), eliminating the major apoptotic response to DNA damage
Overexpression of anti-apoptotic Bcl-2 family members (e.g., BCL-2 in follicular lymphoma, where the t(14;18) translocation places BCL2 under the immunoglobulin heavy chain enhancer)
Overexpression of IAPs (inhibitor of apoptosis proteins) such as survivin and XIAP, which directly inhibit caspases
Loss of death receptors or defects in death receptor signaling
Activation of survival pathways (PI3K-AKT, NF-κB) that transcriptionally upregulate anti-apoptotic genes

Therapeutic strategies that target apoptosis pathways include BH3 mimetics (e.g., venetoclax, which inhibits BCL-2) and MDM2 inhibitors that reactivate p53 in tumors retaining wild-type TP53. These agents exploit the specific apoptotic defects present in cancer cells, a concept discussed further in Molecular Treatment for Cancer.

Hallmarks of Cancer

In 2000, Douglas Hanahan and Robert Weinberg proposed that the complexity of cancer can be reduced to a set of underlying principles—the hallmarks of cancer. The original six hallmarks were expanded to ten in 2011. Each hallmark corresponds to a cellular capability acquired through the molecular alterations described above.

Sustaining Proliferative Signaling

Normal cells require growth factor stimulation to enter and progress through the cell cycle. Cancer cells acquire the ability to sustain proliferative signaling through:

Autocrine stimulation: producing their own growth factors (e.g., PDGF in glioblastoma)
Receptor overexpression or amplification: increasing receptor density so that low ligand concentrations are sufficient (e.g., EGFR amplification in glioblastoma)
Constitutively active downstream effectors: mutations in RAS, BRAF, PIK3CA that activate signaling without ligand
Loss of negative feedback: mutations that disable feedback loops, such as loss of the RAS GTPase-activating protein NF1

Evading Growth Suppressors

Tumor suppressor pathways that normally restrain proliferation must be disabled. The two most important are the RB pathway and the p53 pathway. RB loss or inactivation of CDK inhibitors (p16, p21, p27) allows unscheduled S phase entry. p53 loss eliminates the DNA damage checkpoint and apoptosis response. Together, these alterations permit cells to proliferate despite genomic damage.

Activating Invasion and Metastasis

Metastasis—the spread of cancer cells to distant organs—is responsible for approximately 90% of cancer-related deaths. The molecular basis of invasion and metastasis involves:

Loss of E-cadherin: E-cadherin is a cell-cell adhesion molecule that maintains epithelial integrity. Loss of E-cadherin expression, often through CDH1 mutation or promoter hypermethylation, is a hallmark of the epithelial-to-mesenchymal transition (EMT).
EMT transcription factors: SNAIL, SLUG, TWIST, and ZEB1/2 repress epithelial genes and activate mesenchymal genes, conferring migratory and invasive properties.
Matrix metalloproteinases (MMPs): secreted proteases that degrade the extracellular matrix, allowing invasion through basement membranes and stromal tissue.
Angiogenesis: tumor growth beyond 1–2 mm³ requires new blood vessel formation. Vascular endothelial growth factor (VEGF) is the key driver; anti-VEGF therapies (e.g., bevacizumab) are used clinically.

The remaining hallmarks—resisting cell death, enabling replicative immortality, inducing angiogenesis, evading immune destruction, deregulating cellular energetics, and genome instability and mutation—are equally important. Together, these ten hallmarks provide a conceptual framework for understanding how the molecular alterations described in this article translate into the malignant phenotype. For a visual overview of these processes, the Cancer Cell Diagram may be helpful.

Methods to Study the Molecular Basis of Cancer

Next-Generation Sequencing

Next-generation sequencing (NGS) has revolutionized cancer genomics by enabling comprehensive analysis of tumor genomes at base-pair resolution. Key applications include:

Whole-genome sequencing (WGS): identifies all mutations, structural variants, and copy number alterations in a tumor genome
Whole-exome sequencing (WES): sequences the protein-coding regions (~1.5% of the genome) at lower cost, identifying coding mutations
Targeted gene panels: sequence 50–500 cancer-related genes, providing rapid, clinically actionable results
RNA sequencing (RNA-seq): measures gene expression, identifies fusion genes, and quantifies isoform usage
Methylation sequencing (bisulfite sequencing): maps DNA methylation patterns, identifying epigenetically silenced genes

NGS data analysis involves alignment to the reference genome, variant calling, and annotation. Key challenges include distinguishing true somatic mutations from sequencing errors and germline variants, and interpreting variants of uncertain significance. The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have generated comprehensive genomic profiles for most cancer types, providing a public resource for the research community.

Functional Genomics and CRISPR Screens

While sequencing identifies candidate cancer genes, functional validation requires experimental manipulation. CRISPR-Cas9 technology has made this straightforward:

Design single-guide RNAs (sgRNAs) targeting the gene of interest
Deliver Cas9 and sgRNA into cells via lentiviral transduction or electroporation
Select or screen for the desired phenotype (e.g., proliferation, drug resistance, migration)
Validate with rescue experiments (expressing a wild-type or mutant cDNA)

Pooled CRISPR screens can interrogate thousands of genes simultaneously. In a typical dropout screen, a library of sgRNAs targeting all ~20,000 genes is transduced into a cell population; cells are propagated for multiple doublings; and sgRNA representation is quantified by sequencing. sgRNAs that are depleted encode genes essential for proliferation or survival under the selected condition. This approach has identified genes required for cancer cell viability, drug resistance, and immune evasion.

Animal Models

Genetically engineered mouse models (GEMMs) remain essential for studying cancer biology in vivo. Common approaches include:

Conventional knockout: germline deletion of a tumor suppressor gene (e.g., Trp53^-/-^ mice develop lymphomas and sarcomas)
Conditional knockout: tissue-specific deletion using Cre-loxP or Flp-FRT systems (e.g., Villin-Cre;Apc^fl/fl^ mice develop intestinal adenomas)
Knock-in: introduction of oncogenic mutations (e.g., Kras^LSL-G12D^ mice, where the mutant allele is expressed after Cre-mediated removal of a stop cassette)
Patient-derived xenografts (PDX): implantation of human tumor tissue into immunodeficient mice, preserving the tumor's molecular heterogeneity

Organoid cultures—three-dimensional epithelial structures grown from stem cells in Matrigel—provide a middle ground between cell lines and animal models. Tumor organoids can be established from patient biopsies, genetically manipulated with CRISPR, and used for drug screening. They recapitulate many aspects of the original tumor, including mutational profile and drug response. Detailed protocols for these approaches are available in Current Protocols in Molecular.

Common Pitfalls in Understanding Cancer Molecular Biology

Misconception: Cancer is Caused by a Single Mutation

A frequent error is to think that one mutation is sufficient to cause cancer. In reality, cancer develops through the accumulation of multiple mutations over time. Colorectal cancer, for example, typically requires mutations in APC, KRAS, TP53, and SMAD4, among others, progressing through defined histological stages from adenoma to carcinoma. The age-specific incidence of most cancers increases with the fourth to seventh power of age, consistent with the requirement for 4–7 rate-limiting mutations.

This misconception leads to the related error of expecting that a single targeted therapy will cure cancer. While some cancers are driven by a single dominant oncogene (e.g., BCR-ABL1 in chronic myeloid leukemia), most solid tumors harbor multiple driver mutations, and resistance to targeted therapy inevitably emerges through selection of pre-existing resistant subclones.

Misunderstanding Gain-of-Function vs Loss-of-Function

Students frequently confuse the mutational mechanisms of oncogenes and tumor suppressor genes. The distinction is critical:

Oncogenes are activated by gain-of-function mutations: a single mutant allele produces a hyperactive protein. The mutation is dominant. Examples include KRAS G12D (point mutation), ERBB2 amplification (copy number gain), and BCR-ABL1 fusion (translocation).
Tumor suppressor genes are inactivated by loss-of-function mutations: both alleles must typically be inactivated. The mutation is recessive at the cellular level. Examples include TP53 (missense mutation in one allele, deletion of the other), RB1 (deletion or truncation), and PTEN (mutation plus promoter methylation).

A related error is to assume that all mutations in a tumor suppressor gene are loss-of-function. Some TP53 mutations produce proteins with dominant-negative or gain-of-function activities, complicating this simple dichotomy. Similarly, not all oncogene mutations are activating point mutations; some are gene fusions, amplifications, or overexpression through epigenetic mechanisms.

Other common pitfalls include:

Confusing germline and somatic mutations: Germline mutations are inherited and present in every cell; somatic mutations arise during life and are present only in the tumor. Hereditary cancer syndromes are caused by germline mutations; sporadic cancers are caused by somatic mutations.
Assuming all mutations are drivers: Most mutations in cancer genomes are passengers—they do not contribute to tumorigenesis but accumulate as a consequence of genomic instability. Distinguishing driver from passenger mutations requires functional validation or statistical analysis of mutation recurrence.
Overlooking epigenetic alterations: Cancer is not solely a genetic disease. DNA methylation, histone modifications, and chromatin remodeling contribute to oncogene activation and tumor suppressor silencing. Promoter hypermethylation of MLH1 in sporadic colorectal cancer phenocopies Lynch syndrome.
Ignoring the tumor microenvironment: Cancer cells do not act in isolation. Fibroblasts, immune cells, endothelial cells, and the extracellular matrix all influence tumor progression and response to therapy.

Frequently Asked Questions

What is the molecular basis of cancer?

The molecular basis of cancer is the set of genetic and epigenetic alterations that collectively drive malignant transformation. These alterations include activating mutations in oncogenes, inactivating mutations in tumor suppressor genes, defects in DNA repair pathways that cause genomic instability, and epigenetic changes that alter gene expression. The accumulation of these changes over time, through the process of clonal evolution, produces a tumor with the hallmarks of cancer: sustained proliferative signaling, evasion of growth suppressors, resistance to apoptosis, replicative immortality, angiogenesis, invasion and metastasis, immune evasion, and metabolic reprogramming.

How do oncogenes and tumor suppressors differ?

Oncogenes are mutated or overexpressed versions of proto-oncogenes that drive cell proliferation. They act dominantly: a single mutant allele is sufficient. Tumor suppressor genes encode proteins that restrain cell growth; they act recessively, typically requiring inactivation of both alleles. Oncogene mutations are gain-of-function (the protein is hyperactive), while tumor suppressor mutations are loss-of-function (the protein is inactive or absent). Examples of oncogenes include RAS, MYC, and ERBB2; examples of tumor suppressors include TP53, RB1, and PTEN.

What is the two-hit hypothesis?

The two-hit hypothesis, proposed by Alfred Knudson in 1971, states that both alleles of a tumor suppressor gene must be inactivated for tumor development. In hereditary cancer syndromes, one mutant allele is inherited in the germline, so only one additional somatic hit is required. In sporadic cancers, both hits must occur somatically in the same cell. This model explains the earlier onset and multifocality of hereditary retinoblastoma compared to sporadic retinoblastoma.

Why is p53 called the guardian of the genome?

p53 is called the guardian of the genome because it coordinates the cellular response to DNA damage and other stresses. In response to DNA damage, p53 induces cell cycle arrest (allowing time for repair), senescence, or apoptosis (eliminating damaged cells). By preventing cells with genomic damage from proliferating, p53 maintains genomic integrity. Loss of p53 function, through mutation or inactivation, allows damaged cells to survive and divide, leading to the accumulation of mutations and cancer development. The Biological Basis of Cancer article provides further context on p53 and other key regulators.

What are the hallmarks of cancer?

The hallmarks of cancer are ten capabilities acquired by cancer cells during malignant transformation: (1) sustaining proliferative signaling, (2) evading growth suppressors, (3) resisting cell death, (4) enabling replicative immortality, (5) inducing angiogenesis, (6) activating invasion and metastasis, (7) deregulating cellular energetics, (8) evading immune destruction, (9) genome instability and mutation, and (10) tumor-promoting inflammation. Each hallmark is supported by specific molecular alterations.

How do DNA repair defects cause cancer?

DNA repair defects cause cancer by increasing the mutation rate across the genome—a state called genomic instability. When a specific repair pathway is defective, the types of lesions that pathway normally repairs persist and become fixed as mutations during replication. For example, mismatch repair defects produce point mutations and microsatellite instability; nucleotide excision repair defects produce UV-signature mutations; homologous recombination defects produce chromosomal rearrangements. The increased mutation rate accelerates the accumulation of driver mutations in oncogenes and tumor suppressor genes, speeding up the process of clonal evolution.

What is genomic instability?

Genomic instability is the increased tendency of a genome to acquire mutations, chromosomal rearrangements, and copy number alterations. It is a hallmark of cancer cells and results from defects in DNA repair, DNA replication, or chromosome segregation. Genomic instability generates the genetic diversity that fuels clonal evolution, allowing tumors to adapt to selective pressures such as therapy and immune surveillance. It is both a cause of cancer (by generating driver mutations) and a consequence of cancer (as repair pathways are disrupted during tumor progression). For more on how these molecular changes are detected and used clinically, see Molecular Cancer Diagnosis.

Key Takeaways

Cancer is a genetic disease caused by the accumulation of mutations in oncogenes, tumor suppressor genes, and DNA repair genes, driving clonal evolution toward malignancy.
Oncogenes act dominantly through gain-of-function mutations; tumor suppressor genes act recessively through loss-of-function mutations, often requiring two hits as described by Knudson's hypothesis.
p53 is the most frequently mutated gene in cancer and serves as the central integrator of DNA damage responses, cell cycle arrest, and apoptosis.
Defects in DNA repair pathways (MMR, NER, HR, NHEJ, BER) cause genomic instability and predispose to specific cancer types, as exemplified by hereditary cancer syndromes.
Cancer cells evade apoptosis through p53 loss, Bcl-2 family alterations, and activation of survival pathways, providing therapeutic targets for BH3 mimetics and MDM2 inhibitors.
The ten hallmarks of cancer provide a unifying framework linking molecular alterations to the cellular capabilities required for malignant growth and metastasis.
Modern cancer research integrates next-generation sequencing, CRISPR functional genomics, and animal models to identify driver mutations and develop targeted therapies.